The Business Standard's Smart Investor (SI) reports focus on in-depth analysis and timely news concerning strategic investment trends, business deals, and financial manoeuvres within the corporate world.
The Business Standard's Smart Investor (SI) reports focus on in-depth analysis and timely news concerning strategic investment trends, business deals, and financial manoeuvres within the corporate world.
BHEL, ICICI Bank and ITC slump
Reliance Industries, ITC and ICICI Bank among the top losers
BSE-midcaps and small caps underperform broader markets
BHEL, ICICI Bank and ITC slump
BSE-midcaps and small caps underperform broader markets
BHEL is the top Sensex loser, down over 3%
Pharma shares buck trend
SGX Nifty was down 19 points at 5973.50
Auto, Realty bucks trend
BSE- mid-cap & small-cap indices trade mixed
Q3 gross non performing assets have increased to 2.41% from 1.48%, while Net NPA to 1.12% from 0.51% on yoy basis.
Q3 same-store sales (SSS) growth at 16.1% against an analyst expectation of around 19-20%.
Q3 same store sales growth of 16.1% year-on-year is lowest in last 13 quarters.
USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.
Q3 EBIDTA has declined 27.4% to Rs 138 crore against Rs 190 crore over the previous year quarter
Q3 net loss at Rs 755 crore mainly due to finance cost of Rs 401 crore and a one-time cost of Rs 275 crore due to re-delivery of aircraft.
Reported over three-fold increase in its net profit for the quarter ended December 31, 2012, at Rs 28 crore against Rs 9 crore in a year ago quarter.
Shares slump nearly 6%
Q3 net loss at Rs 755 crore mainly due to finance cost of Rs 401 crore and a one-time cost of Rs 275 crore due to re-delivery of aircraft.
Reported over three-fold increase in its net profit for the quarter ended December 31, 2012, at Rs 28 crore against Rs 9 crore in a year ago quarter.